Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CX3CR1 and CCR2: dynamic myeloid cell states across inflammatory diseases with implications for oral health and disease.

Frontiers in immunology·2026
Same author

A human liver organoid platform for hepatotoxicity assessment: evaluation using reference compounds.

Frontiers in toxicology·2026
Same author

Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model.

Frontiers in oncology·2026
Same author

Interplay between microRNAs and TGF-β signaling in T cells: implications for Th9 differentiation and immune pathogenesis.

Frontiers in immunology·2026
Same author

A Trim21-GSDMD Axis Links Psychosocial Stress to IL-1β-Driven Neuroinflammation and Blood-Brain Barrier Dysfunction in a Rat Model of Repeated Social Defeat.

ACS chemical neuroscience·2026
Same author

The caspase 11/gasdermin D pathway is a key driver of stress-induced neuroinflammation and behavioral dysfunction in rats.

Neurochemistry international·2026

Related Experiment Video

Updated: Jun 14, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Enhancing cellular cancer vaccines.

Edward P Cohen1, Amla Chopra, InSug O-Sullivan

  • 1Department of Microbiology & Immunology, University of Illinois College of Medicine, 835 South Wolcott Ave., Chicago, IL 60612, USA. epcohen@uic.edu

Immunotherapy
|March 31, 2010
PubMed
Summary

Cellular cancer vaccines show limited therapeutic benefits due to targeting non-specific tumor antigens. A novel strategy enriches vaccines for tumor-specific cells to improve cancer immunotherapy efficacy.

Keywords:
cancer vaccinedNA vaccinedendritic cellenriched vaccinefibroblastleukapheresistumor dNA

More Related Videos

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Related Experiment Videos

Last Updated: Jun 14, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • Cellular cancer vaccines are investigated for cancer patient management.
  • Current vaccines offer limited long-term therapeutic benefits and modest survival improvements.
  • A key challenge is the low proportion of tumor-specific antigens in malignant cells, leading to insufficient immune responses.

Purpose of the Study:

  • To review and characterize various types of cellular cancer vaccines.
  • To present a novel strategy for enriching cellular vaccines with tumor-immunity-inducing cells.
  • To discuss the advantages and disadvantages of cellular cancer vaccines in immunotherapy.

Main Methods:

  • Review of existing cellular cancer vaccine strategies.
  • Description of a unique enrichment strategy using a mouse breast cancer model.
  • Analysis of advantages and disadvantages of cancer immunotherapy with cellular vaccines.

Main Results:

  • Existing cellular cancer vaccines have not yielded significant long-term therapeutic benefits.
  • A novel strategy was developed to enrich cellular vaccines for cells that induce tumor immunity.
  • The study outlines the pros and cons of employing cellular vaccines in cancer immunotherapy.

Conclusions:

  • Current cellular cancer vaccines face limitations in eliciting robust anti-tumor immunity.
  • The presented enrichment strategy holds promise for enhancing the efficacy of cellular cancer vaccines.
  • Further research into optimizing cellular vaccines is crucial for improving cancer treatment outcomes.